Siler PanowskiAssociate Director, Solid Tumors at Allogene Therapeutics, USA
Dr. Siler Panowski is an associate director and the head of the solid tumor group at Allogene Therapeutics. He is directly involved in all aspects of the solid tumor portfolio, including strategy, target identification, target validation, and preclinical development. Dr. Panowski has over ten years of industry experience with solid tumor targeting. Prior to joining Allogene, he was instrumental in building the CAR T program under the guidance of Dr. Barbra Sasu at Pfizer, where he ran many of the solid tumor programs that are now part of the Allogene portfolio. He was also the research lead for Pfizer’s BCMA CD3 bispecific, which is now in clinical trials. Dr. Panowski earned his BS in Molecular Biology from UC Berkeley and his PhD in Molecular and Cellular Biology from UCSD/The Salk Institute, before moving to Genentech, where he worked on preclinical discovery and development of ADCs and CD3 bispecifics in the laboratories of Dr. Jagath Junutula and Dr. Richard Scheller.